DiaMedica Therapeutics (DMAC) said Wednesday that it has received regulatory approval from the South African Health Products Regulatory Authority to begin a mid-stage clinical trial with DM199 to treat preeclampsia.
The company said it will conduct the planned two-part mid-stage trial at Tygerberg Hospital in Cape Town, South Africa.
DiaMedica said it expects dosing to begin in Q4, with topline results from part 1a of the trial expected in H1 next year.
Shares of the company were up 1.7% in recent Wednesday premarket activity.
Price: 4.7300, Change: +0.08, Percent Change: +1.72
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.